<DOC>
	<DOCNO>NCT00641381</DOCNO>
	<brief_summary>RATIONALE : Giving high-dose chemotherapy drug , carmustine , etoposide , cyclophosphamide , peripheral blood stem cell transplant stop growth cancer cell stop divide kill . After treatment , stem cell collect patient 's blood return patient replace blood-forming cell destroy chemotherapy . PURPOSE : This clinical trial study side effect give high-dose carmustine , etoposide , cyclophosphamide together stem cell transplant see well work treat patient HIV-associated lymphoma .</brief_summary>
	<brief_title>Carmustine , Etoposide , Cyclophosphamide , Stem Cell Transplant Treating Patients With HIV-Associated Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate feasibility toxicity high-dose chemotherapy comprise carmustine , etoposide , cyclophosphamide follow autologous stem cell infusion patient HIV-associated lymphoma receive combination anti-HIV therapy determine efficiency stem cell collection patient . - To estimate disease-free overall survival patient treat regimen . - To evaluate HIV viral load , CD+4/CD+8 count , immune recovery high-dose anti- lymphoma chemotherapy . - To determine pharmacokinetics high-dose etoposide patient receive highly active anti-retroviral therapy ( HAART ) . OUTLINE : Patients undergo leukapheresis obtain peripheral blood stem cell ( PBSCs ) transplantation . At least 5 day later , patient adequate number collect cell proceed high-dose chemotherapy . - High-dose chemotherapy : Patients receive carmustine IV 4 hour day -7 -5 , etoposide IV 4 hour day -4 , cyclophosphamide IV day -2 . - Autologous PBSC transplantation : Patients receive PBSC infusion day 0 . Patients undergo blood sample collection periodically pharmacokinetic study etoposide . After completion study treatment , patient follow approximately 30 day 100 day , every 3 month 1 year , every 6 month 1 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>HIV seropositive time lymphoma diagnosis Subjects must multidrug regimen ( exclude azidothymidine ) maintain HIV viral load le 50,000 Gc/mL ; CD4 count enrollment le 100 viral load le 10,000 reverse transcriptase polymerase chain reaction ( RtPCR ) ; CD4 count great 100/mm^3 prior start lymphoma chemotherapy great 100/mm^3 least 3 month viral load must less 150,000 gc/ml clinically stable ; prechemotherapy CD4 count available , viral load alone use enrollment The know hematopoietic toxicity AZT ( zidovudine ) prohibit use pretransplant stem cell collection immediate period engraftment posttransplant ; resumption AZT begin evidence stable engraftment ; therefore , AZT resume least 2 month last blood product support use ; since platelet support continue approximately day +14 day experience acquire immune deficiency syndrome ( AIDS ) patient transplanted date , AZT prohibit least 2 month transplant ; therefore , antiHIV drug combination need modify AZT part new regimen Karnofsky performance status &gt; = 70 % Biopsy proven intermediate grade highgrade NonHodgkin 's lymphoma , ( work formulation group DH J , Plasmablastic lymphoma disease state , include first remission give poor risk nature histology ) Hodgkin 's lymphoma subtype except nodular lymphocytic histiocytic ( L &amp; H ) lymphocyte predominant ; tissue histology review City Hope Patients prior marrow involvement must demonstrate &lt; 10 % involvement ( morphology ) pre stem cell collection Pretreatment serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvate transaminase ( SGPT ) &lt; 1.5 x institutional upper limit normal Serum bilirubin &lt; 1.5 x institutional upper limit normal Patients Hepatitis C antibody positive Hepatitis B surface antigen positive without clinical evidence cirrhosis eligible evaluation ; specifically , patient hepatitis C B positive viral load measure ; patient hepatitis B ongoing evidence viral replication may require therapy prior receive high dose chemotherapy ; decision discretion treat physician Serum creatinine &lt; 2 x institutional upper limit normal 24 hour urine creatinine clearance &gt; 60 cc/min Prothrombin time ( PT ) /partial thromboplastin time ( PTT ) &lt; 2 x normal Forced expiratory volume one second ( FEV1 ) diffuse capacity lung carbon monoxide ( DLCO ) &gt; = 50 % predict Left ventricular ejection fraction ( LVEF ) &gt; = 50 % ( 2 dimensional [ 2 D ] echocardiogram multi gated acquisition scan [ MUGA ] scan ) ; absence cardiomyopathy , congestive heart failure dysrhythmia If female child bear potential , must negative serum pregnancy test Subjects must prophylactic regimen pneumocystis pneumonia CD4 count &lt; 200 Subjects complete remission must measurable disease ; measurable disease mean bidimensionally measurable lesion clearly define margin use either medical photograph , computerize axial tomography ( CAT ) scan magnetic resonance imaging ( MRI ) scan , palpation lesion diameter &gt; = 2 cm ; evaluable disease mean lesion unidimensionally measurable , indistinct margin diameter &lt; 0.5 cm , palpable lesion diameter &lt; 2.0 cm , lesion bone ; pleural effusion ascites consider nonevaluable disease ; scan must within 28 day enrollment A minimum 2.5 x 10^6 CD34 cells/kg must collect Hodgkin 's Lymphoma : Partial response standard chemotherapy OR First relapse initial complete remission standard chemotherapy NonHodgkin 's Lymphoma : First complete remission standard chemotherapy high risk feature specify International Prognostic Index ; Partial response standard chemotherapy ; OR Relapse initial complete remission standard chemotherapy Active bacterial fungal infection AIDS relate opportunistic infection within past year , exclude treatmentresponsive Mycobacterium Avium Intracellular infection , treatmentresponsive oral thrush , herpes simplex herpes zoster Active cytomegalovirus ( CMV ) retinitis CMVrelated organ dysfunction ; patient history treat CMV infection exclude Relapse pneumocystis carinii pneumonia within past year AIDS relate syndrome symptom pose perceive excessive risk transplantationrelated morbidity determine principle investigator Intractable severe diarrhea define &gt; 1500 cc diarrheal fluid per day diarrhea cause persistent sever electrolyte abnormality hypoalbuminemia History grade III hemorrhagic cystitis due prior chemotherapy Pregnant nursing woman Any prior malignancy except treat basal cell carcinoma skin ; females cervical dysplasia may include discretion treat physician principle investigator Patients history positive cerebrospinal fluid ( CSF ) cytology become negative intrathecal chemotherapy eligible ; patient negative spinal fluid cytology within thirty day prior enrollment Abnormal cytogenetics screen bone marrow biopsy Psychosocial condition hinder compliance</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>HIV Infections</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>